Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:COCHNASDAQ:DRIONASDAQ:LUCYNASDAQ:PYPD On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeCOCHEnvoy Medical$1.37-4.9%$1.48$1.21▼$3.99$29.22M2.2981,071 shs41,169 shsDRIODarioHealth$0.67-4.5%$0.70$0.50▼$1.55$29.61M1.58284,370 shs265,450 shsLUCYInnovative Eyewear$2.45-8.2%$2.43$1.57▼$13.20$7.59M3.48868,781 shs83,057 shsPYPDPolyPid$3.41-0.6%$2.82$2.30▼$4.49$34.75M1.25120,774 shs248,539 shsElon Musk's Next MoveExplore Elon Musk’s boldest ventures yet—from AI and autonomy to space colonization—and find out how investors can ride the next wave of innovation.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceCOCHEnvoy Medical0.00%-10.16%-17.47%-4.20%-45.63%DRIODarioHealth0.00%-4.99%+1.68%+0.03%-42.09%LUCYInnovative Eyewear0.00%-14.63%-12.19%-34.14%-75.74%PYPDPolyPid0.00%+4.28%+19.65%+15.44%-23.71%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationCOCHEnvoy Medical2.2581 of 5 stars3.52.00.00.01.83.30.0DRIODarioHealth1.6806 of 5 stars3.30.00.00.02.20.81.3LUCYInnovative Eyewear0.8651 of 5 stars0.04.00.00.03.00.00.6PYPDPolyPid3.1243 of 5 stars3.65.00.00.03.11.70.0Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceCOCHEnvoy Medical 3.00Buy$9.25575.18% UpsideDRIODarioHealth 2.67Moderate Buy$2.00200.30% UpsideLUCYInnovative Eyewear 0.00N/AN/AN/APYPDPolyPid 3.20Buy$11.25229.91% UpsideCurrent Analyst Ratings BreakdownLatest LUCY, PYPD, DRIO, and COCH Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails6/9/2025PYPDPolyPidHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetBuy ➝ Buy$11.00 ➝ $13.006/5/2025PYPDPolyPidRoth CapitalSubscribe to MarketBeat All Access for the recommendation accuracy ratingInitiated CoverageBuy$9.006/2/2025PYPDPolyPidHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingUpgradeBuy$11.005/27/2025COCHEnvoy MedicalAscendiant Capital MarketsSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetBuy ➝ Buy$9.25 ➝ $9.505/19/2025DRIODarioHealthLitchfield Hills ResearchSubscribe to MarketBeat All Access for the recommendation accuracy ratingInitiated CoverageBuy$3.004/21/2025COCHEnvoy MedicalAscendiant Capital MarketsSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetBuy ➝ Buy$9.00 ➝ $9.254/14/2025PYPDPolyPidHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$11.00 ➝ $11.00(Data available from 6/15/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookCOCHEnvoy Medical$212K137.82N/AN/A($0.09) per share-15.22DRIODarioHealth$28.03M1.06N/AN/A$2.14 per share0.31LUCYInnovative Eyewear$1.71M4.44N/AN/A$8.61 per share0.28PYPDPolyPidN/AN/AN/AN/A$0.75 per shareN/ACompare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateCOCHEnvoy Medical-$29.91M-$1.38N/AN/AN/A-7,607.55%N/A-262.28%8/11/2025 (Estimated)DRIODarioHealth-$59.43M-$0.56N/AN/AN/A-205.62%-72.16%-40.74%8/6/2025 (Estimated)LUCYInnovative Eyewear-$6.66M-$3.99N/A∞N/A-514.01%-115.86%-105.40%N/APYPDPolyPid-$29.02M-$4.30N/A∞N/AN/A-624.10%-129.28%8/13/2025 (Estimated)Latest LUCY, PYPD, DRIO, and COCH EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/14/2025Q1 2025DRIODarioHealth-$0.07-$0.14-$0.07-$0.14$7.48 million$6.75 million5/14/2025Q1 2025PYPDPolyPid-$0.80-$0.70+$0.10-$0.70N/AN/A5/13/2025Q1 2025LUCYInnovative Eyewear-$0.73-$0.72+$0.01-$0.72$1.00 million$0.46 million3/28/2025Q4 2024COCHEnvoy Medical-$0.33-$0.45-$0.12-$0.45$0.07 million$0.04 million3/24/2025Q4 2024LUCYInnovative Eyewear-$1.16-$0.41+$0.75-$0.41$1.00 million$1.00 millionCompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthCOCHEnvoy MedicalN/AN/AN/AN/AN/ADRIODarioHealthN/AN/AN/AN/AN/ALUCYInnovative EyewearN/AN/AN/AN/AN/APYPDPolyPidN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioCOCHEnvoy MedicalN/A0.790.61DRIODarioHealth0.351.571.32LUCYInnovative EyewearN/A16.8315.22PYPDPolyPid0.081.311.00Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipCOCHEnvoy Medical8.59%DRIODarioHealth33.39%LUCYInnovative Eyewear0.96%PYPDPolyPid26.47%Insider OwnershipCompanyInsider OwnershipCOCHEnvoy Medical58.90%DRIODarioHealth11.20%LUCYInnovative Eyewear6.42%PYPDPolyPid24.70%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableCOCHEnvoy Medical3421.33 million8.00 millionNot OptionableDRIODarioHealth20044.46 million28.47 millionOptionableLUCYInnovative Eyewear93.10 million2.29 millionNot OptionablePYPDPolyPid8010.19 million7.67 millionNo DataLUCY, PYPD, DRIO, and COCH HeadlinesRecent News About These CompaniesFY2026 Earnings Estimate for PolyPid Issued By HC WainwrightJune 14 at 2:17 AM | americanbankingnews.comPESG Research Update: PolyPid's SHIELD II Trial Delivers Transformative Phase 3 Topline Results - Paradigm Shift in Surgical Infection PreventionJune 11, 2025 | globenewswire.comPESG Research Update: PolyPid SHIELD's II Delivers Transformative Phase 3 Topline Results - Paradigm Shift in Surgical Infection PreventionJune 11, 2025 | globenewswire.comPolyPid Announces Positive Topline Results from Phase 3 SHIELD II Trial: D-PLEX₁₀₀ Demonstrated Significant Reduction in Surgical Site Infections and Successfully Met ...June 11, 2025 | seekingalpha.comCraig-Hallum Reaffirms Their Buy Rating on PolyPid (PYPD)June 11, 2025 | theglobeandmail.comPolyPid reports positive phase 3 surgical infection drug trialJune 11, 2025 | en.globes.co.ilNano-Cap PolyPid's Lead Drug Candidate Cuts Surgical Infection Risk by 38% In Phase 3 TrialJune 11, 2025 | finance.yahoo.comPolyPid price target raised to $13 from $11 at H.C. WainwrightJune 11, 2025 | msn.comPolyPid (NASDAQ:PYPD) Price Target Raised to $13.00June 11, 2025 | americanbankingnews.comPolyPid shares surge on successful D-PLEX100 trial resultsJune 9, 2025 | in.investing.comBriefCast Publishes Transcript: PolyPid Ltd. SHIELD II Phase 3 Trial Topline Results Call TranscriptJune 9, 2025 | globenewswire.comPolyPid’s D-PLEX100 Achieves Positive Phase 3 Results in SHIELD II TrialJune 9, 2025 | tipranks.comPolyPid Announces Positive Topline Results from Phase 3 SHIELD II Trial: D-PLEX₁₀₀ Demonstrated Significant Reduction in Surgical Site Infections and Successfully Met Primary and All Key Secondary EndpointsJune 9, 2025 | globenewswire.comRoth Capital Estimates PolyPid's Q2 Earnings (NASDAQ:PYPD)June 9, 2025 | americanbankingnews.comPolyPid to Host Conference Call and Webcast to Discuss D-PLEX₁₀₀ SHIELD II Phase 3 Trial Topline Results on Monday, June 9, 2025June 8, 2025 | finance.yahoo.comPolyPid Ltd. to Host Conference Call on June 9 to Report Topline Data from SHIELD II Phase 3 Trial for D-PLEX100June 6, 2025 | quiverquant.comPolyPid to Host Conference Call and Webcast to Discuss D-PLEXâ‚₀₀ SHIELD II Phase 3 Trial Topline Results on Monday, June 9, 2025June 6, 2025 | globenewswire.comRoth Capital Initiates Coverage of PolyPid (PYPD) with Buy RecommendationJune 6, 2025 | msn.comPolyPid (NASDAQ:PYPD) Now Covered by Analysts at Roth CapitalJune 6, 2025 | americanbankingnews.comHC Wainwright Forecasts PolyPid's Q2 Earnings (NASDAQ:PYPD)June 5, 2025 | americanbankingnews.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeLUCY, PYPD, DRIO, and COCH Company DescriptionsEnvoy Medical NASDAQ:COCH$1.39 -0.05 (-3.47%) As of 06/13/2025 04:00 PM Eastern This is a fair market value price provided by Polygon.io. Learn more.Envoy Medical, Inc., a hearing health company, provides medical technologies for the hearing loss spectrum. Its products include personal sound amplification devices; hearing aids; Esteem fully implanted active middle ear implants; auditory osseointegrated implants; and Acclaim cochlear implants. The company was formerly known as Envoy Medical Corporation and changed its name to Envoy Medical, Inc. in September 2023. Envoy Medical, Inc. was founded in 1995 and is headquartered in White Bear Lake, Minnesota.DarioHealth NASDAQ:DRIO$0.67 -0.03 (-4.52%) Closing price 06/13/2025 04:00 PM EasternExtended Trading$0.70 +0.03 (+5.11%) As of 06/13/2025 05:31 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.DarioHealth Corp. operates as a digital health company in the United States, Canada, the European Union, Australia, and New Zealand. Its digital therapeutics platform and suite of solutions deliver personalized and dynamic interventions driven by data analytics and one-on-one coaching for diabetes, hypertension, weight management, musculoskeletal pain, and behavioral health. The company offers Dario Evolve, a metabolic solution to address metabolic health needs, such as diabetes, pre-diabetes, hypertension, and weight management; Dario Move, which address most common musculoskeletal conditions; Dario Elevate, a behavioral health solution that optimizes access to evidence-based care; and Dario One, a full suite of chronic condition management solution; and Dario blood glucose monitoring systems. It also provides native devices, such as glucose meter, blood pressure cuff, digital scale, and biofeedback sensor device, as well as live coaching services. The company was formerly known as LabStyle Innovations Corp. and changed its name to DarioHealth Corp. in July 2016. DarioHealth Corp. was incorporated in 2011 and is based in New York, New York.Innovative Eyewear NASDAQ:LUCY$2.45 -0.22 (-8.24%) Closing price 06/13/2025 04:00 PM EasternExtended Trading$2.42 -0.04 (-1.43%) As of 06/13/2025 07:52 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Innovative Eyewear, Inc. develops and sells smart eyeglasses and sunglasses. The company's flagship product is Lucyd Lyte glasses that enable the wearer to listen to music, take and make calls, and use voice assistants to perform various smartphone tasks hands-free. It also offers Vyrb, a social media application that enables the user to receive and send posts through Lucyd Lyte smart glasses with voice. In addition, the company launches an application, Lucyd app for iOS/Android users. It sells its products through various e-commerce, and retail store and distribution channels. Innovative Eyewear, Inc. has a license agreement with Lucyd Ltd. The company was incorporated in 2019 and is headquartered in North Miami, Florida. Innovative Eyewear, Inc. is a subsidiary of Lucyd Ltd.PolyPid NASDAQ:PYPD$3.41 -0.02 (-0.58%) Closing price 06/13/2025 04:00 PM EasternExtended Trading$3.38 -0.03 (-0.88%) As of 06/13/2025 07:58 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.PolyPid Ltd., a clinical-stage biopharmaceutical company, developing targeted, locally administered, and prolonged-release therapeutics using its proprietary polymer-lipid encapsulation matrix (PLEX) technology to address unmet medical needs. Its lead product candidate is D-PLEX100, which is in a pivotal Phase 3 confirmatory trial for prevention of surgical site infections (SSIs) in patients undergoing abdominal colorectal surgery with large incisions. It is also developing OncoPLEX, for the treatment of intra-tumoral cancer. PolyPid Ltd. was incorporated in 2008 and is headquartered in Petah Tikva, Israel. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30EcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas MarketBeat Week in Review – 06/09 - 06/13 Alphabet Enters a Bull Market: Is It Time to Buy? Ouster Soars 27% as DoD Grants First 3D LiDAR Approval for Drones Super Micro Computer Stock: 2 Levels Smart Money Is Watching Intel's Price Spikes: Noise, or the First Notes of a Turnaround? IBM Up 10 Days in a Row: What’s Driving the Winning Streak? SoFi Stock’s Next Test: Can It Justify Its Premium Valuation? Ignore the Noise—Samsara Stock Is Still a Strong Buy Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
